

This article was downloaded by:

On: 28 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

### Mixed-Backbone Oligonucleotides Containing Segments of Deoxynucleosides Phosphorothioate and 2'-O-Methylribonucleosides Methylphosphonate: Synthesis and Properties

Maojun Guo; Dong Yu; Sudhir Agrawal

**To cite this Article** Guo, Maojun, Yu, Dong and Agrawal, Sudhir(1999) 'Mixed-Backbone Oligonucleotides Containing Segments of Deoxynucleosides Phosphorothioate and 2'-O-Methylribonucleosides Methylphosphonate: Synthesis and Properties', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 144: 1, 363 – 366

**To link to this Article:** DOI: 10.1080/10426509908546256

**URL:** <http://dx.doi.org/10.1080/10426509908546256>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

# Mixed-Backbone Oligonucleotides Containing Segments of Deoxynucleosides Phosphorothioate and 2'-O-Methylribonucleosides Methylphosphonate: Synthesis and Properties

MAOJUN GUO, DONG YU and SUDHIR AGRAWAL

*Hybridon Inc., 620 Memorial Drive, Cambridge, MA 02139*

Synthesis of mixed-backbone oligonucleotides containing segments of deoxynucleoside phosphorothioate and 2'-O-methylribonucleoside methylphosphonate have been achieved by using *N*-Pent-4-enoyl (PNT) heterocyclic base-protected 2'-O-methylribonucleoside methylphosphonamidites. Use of PNT for heterocyclic base-protection allows the deprotection to be carried out under milder conditions without affecting base labile methylphosphonate internucleotide linkages. New MBOs have reduced phosphorothioate internucleotide linkages while maintaining affinity with target RNA and are stable towards nucleases.

**Keywords:** Phosphorothioate; methylphosphonate; methylphosphonamidite; phosphoramidite; oligonucleotide; antisense

## Introduction


Oligodeoxynucleoside phosphorothioates (PS-oligos) have been studied extensively as antisense agents<sup>[1a]</sup>. To further improve the therapeutic potential of these compounds, mixed backbone oligonucleotides (MBOs) have been developed and studied extensively. MBOs have yielded promising results and are being evaluated in human clinical trials as second-generation antisense oligonucleotides<sup>[1b]</sup>. MBOs contain a segment of PS-oligo, which provides nuclease stability and RNase H activity, and segments of 2'-O-methylribonucleoside at both the 5'- and 3'- ends, which provides increased affinity with the target RNA and a further increase in nuclease stability compared to PS-oligo. As well as having improved biological activity, MBOs are less toxic *in vivo* than are PS-oligos<sup>[1c]</sup>, depending on the sequences and base compositions. In addition, MBOs can be delivered orally<sup>[1d]</sup>.

MBOs containing 2'-O-alkylribonucleosides (2'-O-methyl, 2'-O-propyl) along with phosphodiester linkages at both the 3'- and 5'- ends of PS-oligos have a lower number of phosphorothioate linkages, but these MBOs were found to be less stable against nucleases than were PS-oligos<sup>[1e-f]</sup>.

In continuing our effort to optimize the therapeutic potential of oligonucleotides, our goal is to further minimize phosphorothioate-related side effects (complement activation and

### Synthesis of 2'-*O*-methylribonucleoside methylphosphonamidites

The PNT heterocyclic base-protected 5'-dimethoxytrityl (DMT)-2'-*O*-methylribonucleoside **1** were synthesized by transient silyl protection of the 3'- and 5'- hydroxyl group of the corresponding 2'-*O*-methylribonucleosides, followed by acylation of the exocyclic amino group using pent-4-enoic anhydride (Scheme 1)<sup>11</sup>. After working up and without further purification, the PNT heterocyclic base-protected 2'-*O*-methylribonucleosides in the crude reaction mixture were reacted with dimethoxytrityl chloride to obtain the PNT heterocyclic base-protected 5'-DMT-2'-*O*-methylribonucleoside **1**.



The requisite 2'-*O*-methylribonucleoside methylphosphonamidite monomers **2a-c** were prepared by the initial addition of *N,N*-diisopropylamine to dichloromethylphosphine followed by addition of the appropriate 2'-*O*-methylribonucleosides **1a-c** in a one-pot reaction. Each of the PNT 2'-*O*-methylribonucleoside methylphosphonamidite monomers thus obtained was purified by column chromatography and analyzed by <sup>31</sup>P NMR.

MBOs containing PS-oligo and 2'-*O*-methylribonucleoside methylphosphonate linkages were synthesized using appropriate PNT-protected deoxynucleoside  $\beta$ -cyanoethylphospho-

ramidites<sup>[4]</sup> and 2'-*O*-methylribonucleoside methylphosphonamidites **2a-c** on an automated synthesizer (Expedite 8909, PerSeptive Biosystems). The sequence chosen for this study was an 18mer oligonucleotide complementary to RI $\alpha$  regulatory subunit of the protein kinase A<sup>[5]</sup>. Oligonucleotides **1** to **6** listed in Table 1 were synthesized. To synthesize the PS oligo segment, coupling was carried out using appropriate PNT-protected deoxynucleoside  $\beta$ -cyanoethylphosphoramidites and 1-*H* tetrazole, followed by oxidation with 3*H*-1,2-benzodithiole-3-one-1,1-dioxide. To synthesize segments with 2'-*O*-methylribonucleoside methylphosphonate and phosphodiester linkages, coupling was carried out using PNT-protected 2'-*O*-methylribonucleoside methylphosphonamidites **2a-c** and PNT-protected 2'-*O*-methylribonucleoside  $\beta$ -cyanoethylphosphoramidites, followed by oxidation with *t*-butyl hydroperoxide (*t*-BuOOH, 1M in toluene). DMT was removed at the end of the synthesis cycles of the required sequence. Both the cleavage of oligonucleotides from solid support and the removal of protecting group (PNT) were achieved by using dry gaseous ammonia under 100 psi at room temperature overnight<sup>[6]</sup>. The deprotected oligonucleotides were purified by preparative polyacrylamide gel electrophoresis. The purity and integrity of the oligonucleotides were analyzed by <sup>31</sup>P NMR, MALDI-TOF mass spectrometry and capillary gel electrophoresis (data not shown).

### The design and thermodynamic duplex stability of MBOs

Thermodynamic duplex stability (*T*<sub>m</sub>) of the duplexes formed between the MBOs and the corresponding complementary RNA were determined by measurements of the absorbance at  $\lambda$ 260 nm vs temperature. The *T*<sub>m</sub>s, which represent the average of at least two determinations are summarized in Table 1.

TABLE 1. Thermodynamic duplex stability of MBOs

No.	Oligo Sequences and Modification (5'-3')	<i>T</i> <sub>m</sub> (°C)	$\Delta T_m$ (°C) <sup>#</sup>
<b>1</b>	GCG TGC CTC CTC ACT GGC	63.5	
<b>2</b>	GCG TGC CmUmCm CmUmC ACT GGC	56.2	- 7.3
<b>3</b>	GCG TGC CmUoCm CoUmC ACT GGC	67.2	+ 3.7
<b>4</b>	GmCmG TGC CTC CTC ACUm GmGmC	64.2	+ 0.7
<b>5</b>	GmCoG TGC CTC CTC ACoUm GoGmC	70.3	+ 6.8
<b>6</b>	GmCoGm UoGC CTC CTC ACoUm GoGmC	72.4	+ 8.9

<sup>#</sup>: Compared to oligo **1**;

Normal letters represent 2'-deoxynucleosides; Bold letters represent 2'-*O*-methylribonucleosides;

Lower case letters *o* and *m* represent phosphodiester and methylphosphonate linkages respectively.

rest of the internucleotide linkages are phosphorothioate.

The *T*<sub>m</sub> of oligo **1** (PS-oligo) with complementary RNA is 63.5°C, substitution of five deoxynucleoside phosphorothioates in the middle of oligo **1** with five 2'-*O*-methylribonucleosides methylphosphonate (oligo **2**) resulted in lowering of thermodynamic stability, almost by 1.5°C per substitution. Substitution of six deoxynucleoside phosphorothioates

(four at 3'-end and two at 5'-end) with six 2'-*O*-methylribonucleoside methylphosphonate (oligo 4) shows no compromise in *T<sub>m</sub>* compared to oligo 1. In our earlier studies, we have made similar observations that incorporation of non-ionic linkages in the center of the oligonucleotide affects the thermodynamic stability more than if non-ionic internucleotide linkages are incorporated at the 3'- and 5'-ends<sup>[7]</sup>. Our objective in this study was to reduce the number of phosphorothioate linkages in the oligonucleotide while maintaining its thermodynamic stability. We achieved this goal with oligo 4. To further improve the thermodynamic stability, we introduced alternative methylphosphonate and phosphodiester linkages in the 2'-*O*-methylribonucleoside segment. Oligo 3 and oligo 5 provided us an increase in the *T<sub>m</sub>* of 3.7 °C and 6.8 °C respectively, compared with oligo 1. The increase in *T<sub>m</sub>* was dependent on the number of 2'-*O*-methylribonucleosides, as demonstrated by oligo 6 which has nine 2'-*O*-methylribonucleosides, compared to seven in oligo 5, and showed *T<sub>m</sub>* of 8.9 °C higher than oligo 1. Oligo 5 and Oligo 6 were found to have stabilities towards snake venom phosphodiesterase similar to that of oligo 4 (data not shown).

In summary, the MBOs synthesized here, which contain segments of oligodeoxynucleoside phosphorothioates and 2'-*O*-methyloligoribonucleoside methylphosphonate or alternated methylphosphonate and phosphodiester linkages provide us a means by which number of phosphorothioate internucleotide linkages can be reduced. These MBOs have higher thermodynamic stability and increased resistance towards nucleases. Further studies are ongoing to explore the use these MBOs as antisense agents.

## References

- [1] (a) *Antisense Therapeutics*, S. Agrawal, Ed. Humana Press, Totowa (New Jersey) (1996); (b) S. Agrawal, *Trends in Biotechnology*, **14**, 376 (1996); (c) S. Agrawal, and Q. Zhao, *Antisense & Nucleic Acid Drug Dev.* **8**, 135 (1998); (d) S. Agrawal, *et al Biochem. Pharm.* **50**, 571 (1995); (e) D. Yu, R. P. Iyer, and S. Agrawal, *Bioorg. & Med. Chem.* **4**, 1685 (1996); (f) S. T. Crooke, *et al J. Pharm. Exp. Ther.* **277**, 923 (1996).
- [2] S. Agrawal, M. P. Civiera, J. Goodchild, T. Ikeuchi, and P. C. Zamecnik, *Proc. Natl. Acad. Sci. U. S. A.* **85**, 7448 (1988).
- [3] (a) E. R. Kandimalla, J. Temsamani, and S. Agrawal, *Nucleosides and Nucleotides*, **14**, 1031 (1995); (b) J. M. Kean, S. A. Kipp, P. S. Miller, M. Kulka, and L. Aurelian, *Biochemistry*, **34**, 14617 (1995).
- [4] R. P. Iyer, D. Yu, I. Habus, N. Ho, S. Johnson, T. Devlin, Z. Jiang, W. Zhou, J. Xie, and S. Agrawal, *Tetrahedron*, **53**, 2731 (1997).
- [5] Y. S. Cho-Chung, M. Nesterova, S. Agrawal, and K. Noguchi, *Proc. Am. Assoc. Cancer Res.* **351** (1996).
- [6] R. P. Iyer, D. Yu, J. Xie, W. Zhou, and S. Agrawal, *Bioorg & Med. Chem. Lett.* **7**, 1443 (1997).
- [7] S. Agrawal, Z. Jiang, Q. Zhao, D. Shaw, Q. Cai, A. Roskey, L. Channavajjala, C. Saxinger, and R. Zhang, *Proc. Natl. Acad. Sci. U.S.A.* **94**, 2620 (1997).